Virus-like particle display of HER2 induces potent anti-cancer responses
Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20–30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination...
Main Authors: | Arianna Palladini, Susan Thrane, Christoph M. Janitzek, Jessica Pihl, Stine B. Clemmensen, Willem Adriaan de Jongh, Thomas M. Clausen, Giordano Nicoletti, Lorena Landuzzi, Manuel L. Penichet, Tania Balboni, Marianna L. Ianzano, Veronica Giusti, Thor G. Theander, Morten A. Nielsen, Ali Salanti, Pier-Luigi Lollini, Patrizia Nanni, Adam F. Sander |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-03-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1408749 |
Similar Items
-
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
by: Carla De Giovanni, et al.
Published: (2019-04-01) -
Cancer immunoprevention: from mice to early clinical trials
by: Arianna Palladini, et al.
Published: (2018-06-01) -
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
by: Patrizia Nanni, et al.
Published: (2018-08-01) -
Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems
by: Laurits Fredsgaard, et al.
Published: (2021-05-01) -
The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration
by: Christoph M. Janitzek, et al.
Published: (2021-02-01)